New hope for tough liver cancer: combo therapy targets tumors with vein clots
NCT ID NCT07327788
First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 12 times
Summary
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706), a targeted therapy (bevacizumab), and chemotherapy given directly into the liver artery for people with advanced liver cancer that has spread into the main portal vein. The goal is to see if this treatment can shrink tumors and help people live longer without the cancer growing. About 38 adults who have not had prior treatment for their liver cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATECELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanfang Hospital of Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.